<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440947</url>
  </required_header>
  <id_info>
    <org_study_id>EPZ108859</org_study_id>
    <nct_id>NCT00440947</nct_id>
  </id_info>
  <brief_title>Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection</brief_title>
  <official_title>See Detailed Description</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the efficacy, safety, tolerability and durability of the
      antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC)
      Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by
      randomization to either a simplification regimen of ATV or continuation of ATV +/r for an
      additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1
      infected, HLA-B*5701 negative subjects.

      All subjects who complete the 84-week study will be eligible to enter the treatment extension
      phase and continue for an additional 60 weeks. The purpose of this extension is to obtain
      longer term treatment data in subjects who have completed the 84-week study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the
      Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by
      Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an
      Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects
      followed by an Optional 60-Week Treatment Extension Phase
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA &lt;50 Copies (c) /Milliliter (ml) at the Week 84 Visit</measure>
    <time_frame>Week 84</time_frame>
    <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (&lt;100,000 c/ml and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase</measure>
    <time_frame>Baseline of Randomized Phase</time_frame>
    <description>The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 36 Visit</measure>
    <time_frame>Week 36</time_frame>
    <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 84 Visit</measure>
    <time_frame>Week 84</time_frame>
    <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA &lt;50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 144 Visit</measure>
    <time_frame>Week 144</time_frame>
    <description>Percentage of PAR with HIV-1 RNA &lt;50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/ml at the Week 36 Visit</measure>
    <time_frame>Week 36</time_frame>
    <description>The percentage of PAR with HIV-1 RNA virus &lt;400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 84 Visit</measure>
    <time_frame>Week 84</time_frame>
    <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 144 Visit</measure>
    <time_frame>Week 144</time_frame>
    <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Met the PDVF Criteria at Week 84</measure>
    <time_frame>Week 84</time_frame>
    <description>The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Met the PDVF Criteria at Week 144</measure>
    <time_frame>Week 144</time_frame>
    <description>The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV-1 RNA at Week 36</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV-1 RNA at Week 84</measure>
    <time_frame>Baseline and Week 84</time_frame>
    <description>Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV-1 RNA at Week 144</measure>
    <time_frame>Baseline and Week 144</time_frame>
    <description>Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 36</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 84</measure>
    <time_frame>Baseline and Week 84</time_frame>
    <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 144</measure>
    <time_frame>Baseline and Week 144</time_frame>
    <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84</measure>
    <time_frame>Randomization at Week 36 through Week 84</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144</measure>
    <time_frame>Week 84 through Week 144</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</measure>
    <time_frame>Randomization at Week 36 through Week 84</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</measure>
    <time_frame>Week 84 through Week 144</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Compliance at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Compliance at Week 84</measure>
    <time_frame>Week 84</time_frame>
    <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Compliance at Week 144</measure>
    <time_frame>Week 144</time_frame>
    <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Infection, Human Immunodeficiency Virus I</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Simplification</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)</intervention_name>
    <description>Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen</description>
    <arm_group_label>Continuation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)</intervention_name>
    <description>Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen</description>
    <arm_group_label>Simplification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject is ≥ 18 years of age and has documented evidence of HIV-1 infection. (A female
             is eligible to enter and participate in this study if she is of: non child-bearing
             potential, child bearing potential with a negative pregnancy test and agrees to
             approved contraception methods, or agreement for complete abstinence.)

          -  Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any
             NRTI and no prior therapy with either a PI or NNRTI).

          -  Subject has plasma HIV-1 RNA ≥ 1,000 copies/mL by Roche COBAS AMPLICOR™ (Version 1.5)
             method at screening (if no other documentation of HIV infection is available, a
             positive result here may serve as documentation of HIV infection for this study).

          -  Subject is willing and able to understand and provide written informed consent prior
             to participation in this study.

        Exclusion criteria:

          -  Subject is HLA-B*5701 positive.

          -  Subject testing positive for Hepatitis B or both Hepatitis B and Hepatitis C at
             screening (+ HbsAg)

          -  Genotyping results performed at the screening indicate that the subject has any of the
             following mutations at the reverse transcriptase (RT) enzyme: K65R, L74V, or Y115F, or
             a combination of two or more thymidine analog mutations (M41L, D67N, K70R, K219Q or E)
             that include changes at either L210 or T215, or ≥ 3 of the following protease
             mutations associated with atazanavir resistance: D30, V32, M36, M46, I47, G48, I50,
             I54, A71, G73, V77, V82, I84, N88, and L90.

          -  Women who are pregnant or breastfeeding.

          -  Subject has an active or acute CDC Clinical Category C event at screening. Treatment
             for the acute event must have been completed at least 30 days prior to screening.

          -  Subject is, in the opinion of the investigator, unable to complete the 84-week dosing
             period and protocol evaluations and assessments.

          -  Subject has ongoing clinically relevant pancreatitis or clinically relevant hepatitis
             at screening.

          -  Presence of a newly diagnosed HIV-related opportunistic infection or any medical
             condition requiring acute therapy at the time of enrollment.

          -  Subject suffers from a serious medical condition, such as diabetes, congestive heart
             failure, cardiomyopathy or other cardiac dysfunction (including known, clinically
             significant cardiac conduction system disease, severe first degree atrioventricular
             block [PR interval &gt; 0.26 seconds], second or third-degree atrioventricular block),
             which in the opinion of the investigator would compromise the safety of the subject.

          -  Subject has pre-existing mental, physical, or substance abuse disorder, which in the
             opinion of the investigator would interfere with the subject's ability to comply with
             the dosing schedule and protocol evaluations and assessments.

          -  Subject has a history of inflammatory bowel disease or malignancy, intestinal
             ischemia, malabsorption, or other gastrointestinal dysfunction, which may interfere
             with drug absorption or render the subject unable to take oral medication.

          -  Subject requires treatment with foscarnet, hydroxyurea or other agents with documented
             activity against HIV-1 in vitro within 28 days of study administration.

          -  Subject requires treatment with immunomodulating agents (such as systemic
             corticosteroids, interleukins, vaccines, or interferons) within 28 days prior to
             screening, or subject had received an HIV-1 immunotherapeutic vaccine within 90 days
             prior to screening. Subjects using inhaled corticosteroids are eligible for
             enrollment.

          -  Creatinine clearance &lt;50 mL/min via the Cockroft-Gault method [Cockroft, 1976].

          -  Active alcohol or substance use sufficient, in the investigator's opinion, to prevent
             adequate compliance with study therapy or to increase the risk of developing
             pancreatitis or chemical hepatitis.

          -  Hypersensitivity to any component of the study drugs.

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;5 times the upper
             limit of normal (ULN).

          -  Total bilirubin &gt; 1.5 times the upper limit of normal (ULN).

          -  Subject has any acute laboratory abnormality at screening, which, in the opinion of
             the investigator, would preclude the subject's participation in the study of an
             investigational compound. Any grade 4 laboratory abnormality would exclude a subject
             from study participation.

          -  Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents
             within 28 days prior to screening, or has an anticipated need for these agents within
             the study period.

          -  Enrolled in one or more investigational drug protocols, which may have impacted HIV-1
             RNA suppression.

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study.

          -  Subjects requiring concomitant administration of proton pump inhibitors.

          -  Subjects who require treatment with the prohibited medications within 28 days of
             commencement of investigational product, or an anticipated need during the study.

        Eligibility Criteria for Treatment Extension Phase:

        -Subjects will be eligible to continue in the treatment extension phase (Weeks 84 to 144)
        if they have successfully completed the 84-week study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glastonbury</city>
        <state>Connecticut</state>
        <zip>06033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>2906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909-1711</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00910</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>L Ross, E Dejesus, M Potter, A LaMarca, D Murphy, I Melendez-Rivera, D Ward, P Wannamaker, J Uy, L Patel, H Amrine-Madsen, J Horton. Epidemiological and Genotypic Clustering of HIV infection within North America During 2007 International HIV &amp; Hepatitis Drug Resistance Workshop &amp; Curative Strategies, 8-12 June 2010, Dubrovnik, Croatia, Poster 150.</citation>
  </reference>
  <reference>
    <citation>Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008 Aug 20;22(13):1673-5. doi: 10.1097/QAD.0b013e32830719aa.</citation>
    <PMID>18670229</PMID>
  </reference>
  <reference>
    <citation>• L Ross, K Squires, B Young, E DeJesus, N Bellos, D Murphy, A Rachlis, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Genotypic Screening Impact in ARIES [Atazanavir (ATV) + Ritonavir (/r) + Abacavir/Lamivudine (ABC/3TC) for 36 Weeks Followed By Randomization to ATV +ABC/3TC or ATV/r + ABC/3TC for 48 Wks in HIV-infected, ART Naïve Patients] :Low Rates of Virologic Failure. The 19th Annual Canadian Conference on HIV/AIDS Research, 13-16 May 2010, Saskatoon, Canada. Poster P-169.</citation>
  </reference>
  <reference>
    <citation>K Squires, E DeJesus, N Bellos, D Ward, D Murphy, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial. 48th ICAAC; September 12-15, 2010, Boston, MA. Poster H-204.</citation>
  </reference>
  <reference>
    <citation>K Squires, B Young, E DeJesus, N Bellos, D Murphy, D Sutherland-Phillips, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naive HIV-1 Infected HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial. 48th ICAAC; October 25-28, 2008, Washington, DC. Poster H-1250a.</citation>
  </reference>
  <reference>
    <citation>K Squires, B Young, E DeJesus, N Bellos, D Murphy, D Sutherland-Phillips, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to ATV/Ritonavir (RTV, r), Each in Combination with Abacavir/Lamivudine (ABC/3TC), after Initial Suppression with ABC/3TC + ATV/r in HIV-1 Infected Patients: 84 Week Results of the ARIES Trial. 5th IAS Conference; Cape Town, South Africa. Abstract WELBB103</citation>
  </reference>
  <reference>
    <citation>Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr;11(2):69-79. doi: 10.1310/hct1102-69.</citation>
    <PMID>20542844</PMID>
  </reference>
  <reference>
    <citation>Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.</citation>
    <PMID>20613461</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <results_first_submitted>May 19, 2011</results_first_submitted>
  <results_first_submitted_qc>July 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2011</results_first_posted>
  <disposition_first_submitted>May 14, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 18, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2010</disposition_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NORVIR</keyword>
  <keyword>ARIES</keyword>
  <keyword>EPZICOM</keyword>
  <keyword>REYATAZ</keyword>
  <keyword>HIV</keyword>
  <keyword>simplification</keyword>
  <keyword>Antiretroviral-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants (PAR) were recruited at 66 centers in the United States of America and Canada. HIV-RNA, human immunodeficiency virus-ribonucleic acid; ml, milliliters.</recruitment_details>
      <pre_assignment_details>The study had a 36-week Non-randomized Induction Phase, followed by an 84-week Randomized Phase. All PAR completing 84 weeks were eligible to enter an optional 60-week extension phase (EP); some PAR chose not to continue in the EP. PAR whose HIV-RNA wasn't &lt;50 copies/ml before Week 36 weren't allowed to randomize at Week 36 and were withdrawn.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABC/3TC + ATV/r: Induction Phase</title>
          <description>Abacavir (ABC) 600 milligrams (mg)/lamivudine (3TC) 300 mg fixed-dose combination tablet (FDC) once a day (QD) plus atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
        </group>
        <group group_id="P2">
          <title>ABC/3TC + ATV: Randomization Phase</title>
          <description>Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with 400 mg ATV QD</description>
        </group>
        <group group_id="P3">
          <title>ABC/3TC + ATV/r: Randomization Phase</title>
          <description>Continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
        </group>
        <group group_id="P4">
          <title>ABC/3TC + ATV: Extension Phase</title>
          <description>Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
        </group>
        <group group_id="P5">
          <title>ABC/3TC + ATV/r: Extension Phase</title>
          <description>Continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>36-Week Induction Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="515"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="442">23 PAR without confirmed HIV-RNA&lt;50c/mL prior to Wk 36 couldn’t be randomized but weren’t withdrawn.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Viral Load Response</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Virologic Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kaposi Lesions Requiring Chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Took Exclusionary Medications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Genotype Had Exclusionary Mutations</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fleeing Police; Outstanding Warrants</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>48-Week Randomization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="209"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="185"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Virologic Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trying to Get Pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional 60-Week Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="189"/>
                <participants group_id="P5" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Viral Load Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Virologic Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Terminated Site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Remained in Cuba</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABC/3TC + ATV/r</title>
          <description>All participants starting the Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="515"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated baseline HIV-RNA level</title>
          <description>HIV-1 RNA, Human Immunodeficiency Virus type 1 Ribonucleic acid. HIV-1 viral load was measured as virus copies per milliliter (ml) at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HIV-1 RNA &lt;100,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-1 RNA 100,000-&lt;250,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-1 RNA 250,000-&lt;500,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-1 RNA &gt;=500,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated Baseline CD4+ Cell Count</title>
          <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CD4+ cells &lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cells 50-&lt;200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cells &gt;=200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated Center for Disease Control (CDC) Classification</title>
          <description>AIDS, Acquired Immunodeficiency Syndrome CDC classifications are Asymptomatic, Symptomatic, or AIDs.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asymptomatic HIV Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic (non-AIDS) condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AIDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Baseline CD4+ Cell Count</title>
          <units>cells per cubic millimeter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199" lower_limit="19" upper_limit="754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Baseline HIV-1 RNA Level</title>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.076" lower_limit="2.989" upper_limit="6.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA &lt;50 Copies (c) /Milliliter (ml) at the Week 84 Visit</title>
        <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (&lt;100,000 c/ml and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.</description>
        <time_frame>Week 84</time_frame>
        <population>Intent-to-Treat (ITT)-Exposed Population, Randomized Phase: all PAR exposed to at least one dose of study medication during the Randomized Phase of the study. The primary analysis method was time to loss of virologic response (TLOVR) for the proportion of PAR with HIV-1 RNA &lt;50 c/ml at Week 84 in the Simplification arm and Continuation arms</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA &lt;50 Copies (c) /Milliliter (ml) at the Week 84 Visit</title>
          <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (&lt;100,000 c/ml and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.</description>
          <population>Intent-to-Treat (ITT)-Exposed Population, Randomized Phase: all PAR exposed to at least one dose of study medication during the Randomized Phase of the study. The primary analysis method was time to loss of virologic response (TLOVR) for the proportion of PAR with HIV-1 RNA &lt;50 c/ml at Week 84 in the Simplification arm and Continuation arms</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority would be established between the two arms if the lower limit of the 2-sided 95% confidence interval (CI) on the difference in the percentage of participants with HIV-1 RNA &lt;50 c/mL at Week 84 was -12% or greater.</non_inferiority_desc>
            <p_value>0.140</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-value was obtained from Cochran-Mantel-Haenszel stratified by baseline HIV-1 RNA (&lt;100000/&gt;=100000)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase</title>
        <description>The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.</description>
        <time_frame>Baseline of Randomized Phase</time_frame>
        <population>ITT-E Population: all participants exposed to at least one dose of study medication during the Randomized Simplification Phase</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase</title>
          <description>The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.</description>
          <population>ITT-E Population: all participants exposed to at least one dose of study medication during the Randomized Simplification Phase</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="10.23"/>
                    <measurement group_id="O2" value="39.7" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 36 Visit</title>
        <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.</description>
        <time_frame>Week 36</time_frame>
        <population>ITT-E Population, Induction Phase: all participants exposed to at least one dose of study medication during the Induction Phase of the study</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 36 Visit</title>
          <description>The percentage of PAR with HIV-1 RNA virus &lt;50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load &lt;50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.</description>
          <population>ITT-E Population, Induction Phase: all participants exposed to at least one dose of study medication during the Induction Phase of the study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 84 Visit</title>
        <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA &lt;50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.</description>
        <time_frame>Week 84</time_frame>
        <population>ITT-E Population, Randomized Phase. The secondary analysis methods were Observed (Obs) and missing/discontinuation=failure (M/D=F) analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 84 Visit</title>
          <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA &lt;50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.</description>
          <population>ITT-E Population, Randomized Phase. The secondary analysis methods were Observed (Obs) and missing/discontinuation=failure (M/D=F) analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 144 Visit</title>
        <description>Percentage of PAR with HIV-1 RNA &lt;50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
        <time_frame>Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase: all participants exposed to at least one dose of study medication during the Extension Phase of the study</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;50 c/ml at the Week 144 Visit</title>
          <description>Percentage of PAR with HIV-1 RNA &lt;50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=50 c/ml, or had an unconfirmed HIV RNA &gt;=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
          <population>ITT-Extension Population, Extension Phase: all participants exposed to at least one dose of study medication during the Extension Phase of the study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/ml at the Week 36 Visit</title>
        <description>The percentage of PAR with HIV-1 RNA virus &lt;400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
        <time_frame>Week 36</time_frame>
        <population>ITT-E Population, Induction Phase</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/ml at the Week 36 Visit</title>
          <description>The percentage of PAR with HIV-1 RNA virus &lt;400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA &lt;400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
          <population>ITT-E Population, Induction Phase</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 84 Visit</title>
        <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
        <time_frame>Week 84</time_frame>
        <population>ITT-E Population, Randomized Phase</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 84 Visit</title>
          <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
          <population>ITT-E Population, Randomized Phase</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 144 Visit</title>
        <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
        <time_frame>Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved HIV-1 RNA &lt;400 c/ml at the Week 144 Visit</title>
          <description>Percentage of PAR with HIV-1 RNA &lt;400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (&lt;100,000 and &gt;=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA &lt;400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA &lt;400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to &gt;=400 c/ml, or had an unconfirmed HIV RNA &gt;=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.</description>
          <population>ITT-Extension Population, Extension Phase</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M/D=F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36</title>
        <description>The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
        <time_frame>Week 36</time_frame>
        <population>ITT-E Population, Induction Phase</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36</title>
          <description>The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
          <population>ITT-E Population, Induction Phase</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Protocol-defined virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure to achieve &lt;400 c/ml by Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed rebound after achieving &lt;400 c/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Met the PDVF Criteria at Week 84</title>
        <description>The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
        <time_frame>Week 84</time_frame>
        <population>ITT-Exposed Population, Randomized Phase. TLOVR. One participant met PDVF criteria at Week 36 and was included in the Week 36 PDVF but had been randomized; this participant is therefore also included in this PDVF tabulation.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the PDVF Criteria at Week 84</title>
          <description>The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
          <population>ITT-Exposed Population, Randomized Phase. TLOVR. One participant met PDVF criteria at Week 36 and was included in the Week 36 PDVF but had been randomized; this participant is therefore also included in this PDVF tabulation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Protocol-defined virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed rebound after achieving &lt;400 c/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Met the PDVF Criteria at Week 144</title>
        <description>The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
        <time_frame>Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase. TLOVR.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the PDVF Criteria at Week 144</title>
          <description>The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA &lt;400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound &gt;=400 c/ml after achieving HIV-1 &lt;400 c/ml.</description>
          <population>ITT-Extension Population, Extension Phase. TLOVR.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Protocol-defined virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed rebound after achieving &lt;400 c/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV-1 RNA at Week 36</title>
        <description>Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>ITT-E Population, Induction Phase. Observed Population. Participants could only be included in the analysis if they had completed a Week 36 visit and had a viral load result obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV-1 RNA at Week 36</title>
          <description>Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
          <population>ITT-E Population, Induction Phase. Observed Population. Participants could only be included in the analysis if they had completed a Week 36 visit and had a viral load result obtained during that visit period.</population>
          <units>log10 c/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.241" spread="0.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV-1 RNA at Week 84</title>
        <description>Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
        <time_frame>Baseline and Week 84</time_frame>
        <population>ITT-E Population, Randomized Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 84 visit and had a viral load result obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV-1 RNA at Week 84</title>
          <description>Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
          <population>ITT-E Population, Randomized Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 84 visit and had a viral load result obtained during that visit period.</population>
          <units>log10 c/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.261" spread="0.681"/>
                    <measurement group_id="O2" value="-3.270" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV-1 RNA at Week 144</title>
        <description>Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
        <time_frame>Baseline and Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 144 visit and had a viral load result obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV-1 RNA at Week 144</title>
          <description>Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.</description>
          <population>ITT-Extension Population, Extension Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 144 visit and had a viral load result obtained during that visit period.</population>
          <units>log10 c/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.291" spread="0.675"/>
                    <measurement group_id="O2" value="-3.239" spread="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 36</title>
        <description>Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>ITT-E Population, Induction Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 36 visit and had a cell count obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 36</title>
          <description>Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.</description>
          <population>ITT-E Population, Induction Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 36 visit and had a cell count obtained during that visit period.</population>
          <units>cells/millimeters cubed (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.4" spread="121.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 84</title>
        <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
        <time_frame>Baseline and Week 84</time_frame>
        <population>ITT-E Population, Randomized Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 84 visit and had a cell count obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 84</title>
          <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
          <population>ITT-E Population, Randomized Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 84 visit and had a cell count obtained during that visit period.</population>
          <units>cells/millimeters cubed (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.7" spread="157.65"/>
                    <measurement group_id="O2" value="282.9" spread="150.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 144</title>
        <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
        <time_frame>Baseline and Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 144 visit and had a cell count obtained during that visit period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 144</title>
          <description>A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.</description>
          <population>ITT-Extension Population, Extension Phase. Observed Population. Participants withdrew as the study progressed; participants could only be included in the analysis if they had completed a Week 144 visit and had a cell count obtained during that visit period.</population>
          <units>cells/millimeters cubed (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.7" spread="161.98"/>
                    <measurement group_id="O2" value="325.1" spread="178.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
        <time_frame>Baseline through Week 36</time_frame>
        <population>Participants in the ITT-E Population (Induction Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure genotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
          <population>Participants in the ITT-E Population (Induction Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure genotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with paired genotypes at baseline and VF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with treatment-emergent mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NNRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with major PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with minor PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
        <time_frame>Randomization at Week 36 through Week 84</time_frame>
        <population>Participants in the ITT-E Population (Randomized Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure genotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
          <population>Participants in the ITT-E Population (Randomized Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure genotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with paired genotypes at baseline and VF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with treatment-emergent mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NNRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with major PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with minor PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
        <time_frame>Week 84 through Week 144</time_frame>
        <population>Participants in the ITT-Extension Population (Extension Phase) who met the confirmed virologic failure criteria with paired baseline and virologic failure genotypic evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</description>
          <population>Participants in the ITT-Extension Population (Extension Phase) who met the confirmed virologic failure criteria with paired baseline and virologic failure genotypic evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with paired genotypes at baseline and VF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with treatment-emergent mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with NNRTI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with major PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with minor PI mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
        <time_frame>Baseline through Week 36</time_frame>
        <population>Participants in the ITT-E Population (Induction Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure phenotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
          <population>Participants in the ITT-E Population (Induction Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure phenotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with reduced abacavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced lamivudine susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced atazanavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced ritonavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
        <time_frame>Randomization at Week 36 through Week 84</time_frame>
        <population>Participants in the ITT-E population (Randomized Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure phenotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
          <population>Participants in the ITT-E population (Randomized Phase) who met the confirmed virologic failure (CVF) criteria with paired baseline and virologic failure phenotypic evaluations. One participant met CVF criteria at Week 36 and was randomized; these results are included in both the Week 36 and the Randomization through Week 84 results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with reduced abacavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced lamivudine susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced atazanavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced ritonavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
        <time_frame>Week 84 through Week 144</time_frame>
        <population>Participants in the ITT-Extension Population (Extension Phase) who met the confirmed virologic failure criteria with paired baseline and virologic failure phenotypic evaluations</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.</description>
          <population>Participants in the ITT-Extension Population (Extension Phase) who met the confirmed virologic failure criteria with paired baseline and virologic failure phenotypic evaluations</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAR with reduced abacavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced lamivudine susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced atazanavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAR with reduced ritonavir susceptibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Compliance at Week 36</title>
        <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
        <time_frame>Week 36</time_frame>
        <population>ITT-E Population, Induction Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV/r: Induction Phase</title>
            <description>Induction Phase: ABC 600 mg/3TC 300 mg FDC tablet QD plus ATV 300 mg QD + /r 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Compliance at Week 36</title>
          <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
          <population>ITT-E Population, Induction Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
          <units>percent compliance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abacavir/Lamivudine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atazanavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Compliance at Week 84</title>
        <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
        <time_frame>Week 84</time_frame>
        <population>ITT-E Population, Randomized Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Randomized Phase</title>
            <description>Randomized Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Randomized Phase</title>
            <description>Randomized Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Compliance at Week 84</title>
          <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
          <population>ITT-E Population, Randomized Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
          <units>percent compliance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abacavir/Lamivudine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" spread="11.62"/>
                    <measurement group_id="O2" value="91.2" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" spread="11.64"/>
                    <measurement group_id="O2" value="91.5" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atazanavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" spread="5.32"/>
                    <measurement group_id="O2" value="92.4" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Compliance at Week 144</title>
        <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
        <time_frame>Week 144</time_frame>
        <population>ITT-Extension Population, Extension Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC + ATV: Extension Phase</title>
            <description>Extension Phase: simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + ATV/r: Extension Phase</title>
            <description>Extension Phase: continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Compliance at Week 144</title>
          <description>Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.</description>
          <population>ITT-Extension Population, Extension Phase. Participants with an unknown number of pills returned (including those whose pill bottles were not returned) were not included in this analysis.</population>
          <units>percent compliance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abacavir/Lamivudine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" spread="12.65"/>
                    <measurement group_id="O2" value="90.1" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" spread="11.07"/>
                    <measurement group_id="O2" value="90.1" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atazanavir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="4.54"/>
                    <measurement group_id="O2" value="91.4" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Data are cumulative. If an adverse event (AE) occurs in the Induction Phase (IP) at &gt;=3%, and no new participants experience the AE in later phases, the participants who experienced the AE in the IP are carried over to the Randomization Phase and to the Extension Phase (if they remain in the study) if the incidence is &gt;=3% for at least one arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>ABC/3TC + ATV/r: Induction Phase</title>
          <description>Induction Phase: participants in the Safety Population (participants exposed to at least one dose of investigational product) receiving abacavir (ABC) 600 milligrams (mg)/lamivudine (3TC) 300 mg fixed-dose combination tablet (FDC) once a day (QD) plus atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD during the first 36 weeks of the study (planned interim analysis)</description>
        </group>
        <group group_id="E2">
          <title>ABC/3TC + ATV: Randomization Phase</title>
          <description>Randomization Phase: participants in the Safety Population receiving a simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV QD; includes serious adverse events (SAEs) that occurred during induction phase</description>
        </group>
        <group group_id="E3">
          <title>ABC/3TC + ATV/r: Randomization Phase</title>
          <description>Randomization Phase: participants in the Safety Population receiving continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD; includes SAEs that occurred during induction phase</description>
        </group>
        <group group_id="E4">
          <title>ABC/3TC + ATV: Extension Phase</title>
          <description>Extension Phase: participants in the Safety Population receiving a simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD</description>
        </group>
        <group group_id="E5">
          <title>ABC/3TC + ATV/r: Extension Phase</title>
          <description>participants in the Safety Population receiving continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Appendicitis, perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Burkitt’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Castleman’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>ViiV Healthcare</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

